A Phase 1/2 Study of Umbralisib, Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Drug Category: Array
Conference Category: Array
Lead Author: Barr P, et al.
Published Date: 08/12/2019
Download Link: /wp-content/uploads/2019/12/ASH2019PBarrU2V.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top